GMAB vs DBVT vs REGN vs HALO

For growth investors, Halozyme Therapeutics, Inc.

(HALO) is the stronger pick with 37. 6% revenue growth year-over-year, versus 1. 0% for Regeneron Pharmaceuticals, Inc. (REGN). Genmab A/S (GMAB) offers the better valuation at 14. 5x trailing P/E (24. 0x forward), making it the more compelling value choice. Analysts rate Genmab A/S (GMAB) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Genmab A/S (GMAB) is the cheapest at 14.

5x versus Halozyme Therapeutics, Inc. at 25. 7x. On forward P/E, Halozyme Therapeutics, Inc. is actually cheaper at 8. 2x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Halozyme Therapeutics, Inc. wins at 0. 36x versus Regeneron Pharmaceuticals, Inc. 's 2. 40x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Regeneron Pharmaceuticals, Inc.

(REGN) delivered a total return of +46. 5%, compared to -69. 6% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: HALO returned +598. 4% versus DBVT's -87. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Halozyme Therapeutics, Inc.

(HALO) is the lower-risk stock at 0. 56β versus DBV Technologies S. A. 's 1. 26β — meaning DBVT is approximately 125% more volatile than HALO relative to the S&P 500. On balance sheet safety, Genmab A/S (GMAB) carries a lower debt/equity ratio of 3% versus 13% for DBV Technologies S. A. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Halozyme Therapeutics, Inc.

(HALO) is pulling ahead at 37. 6% versus 1. 0% for Regeneron Pharmaceuticals, Inc. (REGN). On earnings-per-share growth, the picture is similar: Genmab A/S grew EPS 83. 9% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, GMAB leads at 36. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Genmab A/S (GMAB) is the more profitable company, earning 36.

4% net margin versus 0. 0% for DBV Technologies S. A. — meaning it keeps 36. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HALO leads at 58. 4% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — GMAB leads at 95. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Halozyme Therapeutics, Inc. (HALO) is the more undervalued stock at a PEG of 0. 36x versus Regeneron Pharmaceuticals, Inc. 's 2. 40x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Halozyme Therapeutics, Inc. (HALO) trades at 8. 2x forward P/E versus 24. 0x for Genmab A/S — 15. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DBVT: 137. 7% to $46. 33.

In this comparison, REGN (0.

5% yield) pays a dividend. GMAB, DBVT, HALO do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Halozyme Therapeutics, Inc.

(HALO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 56), +598. 4% 10Y return). Both have compounded well over 10 years (HALO: +598. 4%, DBVT: -87. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: GMAB is a mid-cap high-growth stock; DBVT is a mega-cap quality compounder stock; REGN is a mid-cap deep-value stock; HALO is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.